---
document_datetime: 2024-12-18 11:42:07
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/givlaari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: givlaari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.6471033
conversion_datetime: 2025-12-27 17:34:20.249338
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## GIVLAARI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                |
|----------------------|---------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0020               | Renewal of the marketing authorisation.                 | 19/09/2024                          | 14/11/2024                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of GIVLAARI in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10839 /202311  | Periodic Safety Update EU Single assessment - givosiran | 13/06/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| PSUSA/10839 /202305  | Periodic Safety Update EU Single assessment - givosiran | 11/01/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0018   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/12/2023   | n/a   |                    |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|--------------------|
| IA/0017/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits in test procedure for AS or | 20/10/2023   | n/a   | B.I.b.2.a - Change |

<div style=\"page-break-after: always\"></div>

|                     | changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| II/0013/G           | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                         | 14/09/2023 | n/a        |             |                                   |
| PSUSA/10839 /202211 | Periodic Safety Update EU Single assessment - givosiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/06/2023 | n/a        |             | PRAC Recommendation - maintenance |
| II/0011/G           | This was an application for a group of variations. Update of section 5.3 of the SmPC based on final results from study AS1-GLP18-007 listed as a category 3 study in the RMP; This is a 104-week Subcutaneous Injection Carcinogenicity Study in Sprague Dawley Rats. Update of section 5.3 of the SmPC based on final results from study AS1-GLP18-004; This is a 26- week Subcutaneous Injection Carcinogenicity Study in TgRasH2 Mice. The RMP version 2.6 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 08/06/2023 | 17/06/2024 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0015             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/04/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| PSUSA/10839 /202205 | Periodic Safety Update EU Single assessment - givosiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/12/2022 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/10839 /202111 | Periodic Safety Update EU Single assessment - givosiran                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/06/2022 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0006             | Update of SmPC section 4.8 to add 'blood homocysteine increase' as a new ADR with the frequency 'common' and SmPC section 4.4 to add a related warning. The Package Leaflet is being updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representatives for Malta and Cyprus in the Package Leaflet. An updated RMP version 1.4 was agreed during the procedure: consequences of blood homocysteine increase is being added as a new important potential risk, the clinical and post-marketing exposure is being updated and the due dates for ALN-AS1-002 and ALN-AS1-003 final study reports are being revised. C.I.4 - Change(s) in the SPC, Labelling or PL due to | 05/05/2022 | 24/04/2023 | SmPC and PL | Blood homocysteine levels may be increased in patients with acute hepatic porphyria (AHP), vitamin deficiencies, or chronic kidney disease. During treatment with givosiran, increases in blood homocysteine levels have been observed compared to levels before treatment. The clinical relevance of the elevations in blood homocysteine during treatment with givosiran is unknown. However, homocysteine elevations have been previously associated with an increased risk of thromboembolic events. Measurement of blood homocysteine levels prior to initiating treatment and monitoring for changes during treatment with givosiran is recommended. In patients with elevated homocysteine levels homocysteine-lowering therapy can be considered. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                            |            |            |             |                                                                                                                                                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data A.7 - Administrative change - Deletion of manufacturing sites | 08/02/2022 | n/a        |             |                                                                                                                                                                                                    |
| PSUSA/10839 /202105 | Periodic Safety Update EU Single assessment - givosiran                                                                                                                                                                                                                                 | 02/12/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                  |
| IAIN/0008/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                           | 22/11/2021 | n/a        |             |                                                                                                                                                                                                    |
| PSUSA/10839 /202011 | Periodic Safety Update EU Single assessment - givosiran                                                                                                                                                                                                                                 | 24/06/2021 | 18/08/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10839/202011.                                                         |
| II/0004/G           | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                       | 09/04/2021 | 18/08/2021 | SmPC and PL | The SmPC section 6.5 has been updated accordingly as follows: Glass vial with a fluoropolymer-coated rubber stopper and a flip-off aluminium seal. Each vial contains 1 mL solution for injection. |

<div style=\"page-break-after: always\"></div>

|                     | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |            |                                  |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/10839 /202005 | Periodic Safety Update EU Single assessment - givosiran                                                                                                                                                                                                                                                                                                                                                                                                            | 14/01/2021 | n/a        |                                  | PRAC Recommendation - maintenance |
| IAIN/0003/G         | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                             | 26/11/2020 | 18/08/2021 | SmPC, Annex II, Labelling and PL |                                   |
| IB/0001/G           | This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a                                                                                                         | 06/07/2020 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

| new specification parameter to the specification with   |
|---------------------------------------------------------|
| its corresponding test method                           |